Al Salama Hospital Becomes First in Saudi Arabia—and the Region—to Launch Guselkumab Therapy for IBD Patients

Jeddah, Saudi Arabia – 12 May 2025 – Al Salama Hospital proudly announces the successful administration of Tremfya (Guselkumab), a groundbreaking IL-23 Inhibitor, to the first patient in Saudi Arabia and the wider region for the treatment of Crohn’s Disease and Ulcerative Colitis—outside the clinical trial framework. This milestone positions Saudi Arabia as the second country in the world, after the United States, to offer this innovative biologic therapy in a real-world clinical setting.

Developed by Johnson & Johnson, Guselkumab has recently received approval for IBD treatment, offering new hope to patients with Chronic Inflammatory Bowel Diseases. The therapy, already approved for other autoimmune conditions, marks a new frontier in biologic treatments, delivering targeted action with fewer side effects and long-term relief potential.

“Introducing a new therapy is not just about access—it’s about impact,” said Dr. Maan Alkhattabi, Head of Gastroenterology at Al Salama Hospital. “We’re proud to be the first in the Kingdom to offer Guselkumab as a real option for IBD patients. This is not only a scientific advancement—it’s a message to every patient that world-class care is within reach, right here in Saudi Arabia.”

This achievement underscores Al Salama Hospital’s continued leadership in medical innovation and its commitment to patient-centered care. By bringing globally advanced therapies to the region, the hospital reinforces its role as a regional pioneer in Gastroenterology and a trusted provider of specialized care.